Patent intelligence · US
US 10058521
Omega-3 pentaenoic acid compositions and methods of use
Omega-3 pentaenoic acid compositions and methods of use
Patent details — US 10058521
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 28, 2018
- Expiration
- Aug 23, 2038
- Applicant
- MATINAS BIOPHARMA INC.
- Claims
- 28
- CPC classes
- A61K, A61K31/201, A61K31/202, A61K31/232
Quick answer
US 10058521 (Omega-3 pentaenoic acid compositions and methods of use) is held by MATINAS BIOPHARMA INC.. Status: granted. Granted Aug 28, 2018. Expires Aug 23, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- MATINAS BIOPHARMA INC.
- Grant date
- Expiration
- Claims
- 28
- CPC classes
- A61K, A61K31/201, A61K31/202, A61K31/232, A61K31/40, A61K9/4825
More from MATINAS BIOPHARMA INC.
Related pharmaceutical patents in our USPTO index.
-
US 12409227
Cochleates made with soy phosphatidylserine
granted -
US 11964019
Cochleates made with soy phosphatidylserine
granted -
US 11389407
Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent
granted -
US 11123295
Encholeated antifungal compounds for central nervous system delivery and treatment of Cryptococcus infections
granted -
US 10716860
Cochleates made with soy phosphatidylserine
granted -
US 9775907
Cochleates made with soy phosphatidylserine
granted -
US 8906964
Methods of administering compositions comprising docosapentaenoic acid
granted
Related coverage
Frequently asked questions
What is US patent 10058521?
US 10058521 (Omega-3 pentaenoic acid compositions and methods of use) is held by MATINAS BIOPHARMA INC.. Status: granted. Granted Aug 28, 2018. Expires Aug 23, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10058521?
MATINAS BIOPHARMA INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.
When does US 10058521 expire?
Our index shows an expiration date of Aug 23, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.